Medicortex is introducing, in Finland, a new diagnostic method for a huge need – detection of brain injury and concussion.
Large customer potential and variable clients.
Current company valuation is ca. 6.5 M€.
Investor has an exit opportunity if the company is listing on First North at
Nasdaq Helsinki (to be considered by the BOD when the valuation is above 10 M€).
A team of four people keeps the costs low and the organization lean.
- Using professional sub-contractors with qualified track record